Psychogenics smartcube
WebMay 10, 2024 · PsychoGenics’ drug discovery platforms, SmartCube ®, NeuroCube ® and PhenoCube ®, have been used in shared-risk partnerships with major pharmaceutical companies, resulting in the discovery of... WebThe eCube platform complements PsychoGenics' existing AI-driven phenotypic platforms, including SmartCube, which has successfully advanced multiple compounds into clinical trials. Among these is Ulotaront, a compound developed in collaboration with Sunovion, which is currently in Phase 3 trials for
Psychogenics smartcube
Did you know?
WebSep 27, 2024 · PsychoGenics’ drug discovery platforms, SmartCube ®, NeuroCube ® and PhenoCube ®, have been used in shared-risk partnerships with major pharmaceutical companies, resulting in the discovery of... WebOct 30, 2024 · PsychoGenics’ proprietary, high-throughput SmartCube ® platform combines in vivo behavioral testing with developments in computer vision and modern artificial …
WebApr 11, 2024 · PsychoGenics Inc. has launched eCube, a pharmaco-electroencephalography (pharmacoEEG) platform to support phenotypic drug discovery. The company said that unlike traditional target-based drug discovery, this technique can identify novel treatments with multiple targets. Similar to the company’s AI-enabled, behavior-based platform, … WebApr 6, 2024 · PsychoGenics’ drug discovery platforms SmartCube®, NeuroCube®, and PhenoCube® have been used in shared-risk partnerships with major pharmaceutical …
WebJun 28, 2024 · PsychoGenics’ AI-enabled phenotypic drug discovery platforms SmartCube®, NeuroCube®, PhenoCube® and eCube™ have been used in shared-risk partnerships with major pharmaceutical companies ... WebMay 1, 2024 · We performed chronic social defeat stress (CSDS) in mice and evaluated behavior with PsychoGenics’ SmartCube, a high-throughput unbiased automated phenotyping platform that collects >2000 behavioral features based on machine learning. ... SmartCube analysis after CSDS successfully separated control and defeated-susceptible …
WebApr 11, 2024 · PsychoGenics’ drug discovery platforms SmartCube, NeuroCube, and PhenoCube have been used in shared-risk partnerships with pharmaceutical companies including Sunovion, Roche and Karuna, resulting in the discovery of several novel compounds now in clinical trials or advanced preclinical development.
WebSep 25, 2024 · PsychoGenics’ drug discovery platforms, SmartCube®, NeuroCube®, PhenoCube®, and eCube ™ have been used in shared risk partnerships with biotech pharma companies including Sunovion, Roche ... jesus shall reign where\u0027er the sun gettyWebPsychoGenics.....SmartCube platform. PsychoGenics said Sunovion chose to move forward with the development of SEP-363856, while PsychoGenics.....development of the compound and is eligible for royalties (see BioCentury, Oct. 12, 2015 ). PsychoGenics Inc.... Read More. BioCentury Dec 13, 2016. jesus shall reign where the sun lyricsWebThe eCube platform complements PsychoGenics' existing AI-driven phenotypic platforms, including SmartCube, which has successfully advanced multiple compounds into clinical trials. Among these is Ulotaront, a compound developed in collaboration with Sunovion, which is currently in Phase 3 trials for schizophrenia, depression, and generalized ... inspire counseling center lake forestWebApr 11, 2024 · PsychoGenics Inc. has launched eCube, a pharmaco-electroencephalography (pharmacoEEG) platform to support phenotypic drug discovery. The company said that … jesus shaped peopleWebMay 10, 2024 · PsychoGenics’ drug discovery platforms, SmartCube ®, NeuroCube ® and PhenoCube ®, have been used in shared-risk partnerships with major pharmaceutical companies, resulting in the discovery of several novel compounds now in clinical trials or advanced preclinical development. inspire counseling durant okWebMar 5, 2015 · PsychoGenics developed three comprehensive high-throughput systems, SmartCube(®), NeuroCube(®) and PhenoCube(®) systems, to increase the efficiency of the drug screening and phenotyp … Drug testing with traditional behavioral assays constitutes a major bottleneck in the development of novel therapies. jesus shall sit on the throne of davidWebJan 31, 2024 · and PsychoGenics Inc.), Formulation: oral ・ SEP-378614 is a novel CNS -active molecule. Sunovion discovered SEP -378614 in collaboration with PsychoGenics using its in vivo phenotypic SmartCube ® platform and associated artificial intelligence algorithms. Preclinical studies suggest that it - may have rapid onset and long lasting … jesus shares his glory with us